| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $407,062 | 12 | 20 |
Sells | $5,358,729 | 48 | 80 |
| Heron Patrick J | director | 9 | $373,039 | 0 | $0 | $373,039 |
| Watanabe Todd Franklin | See Remarks | 1 | $14,482 | 10 | $1.31M | $-1.3M |
| Matsuda Masaru | See Remarks | 1 | $11,775 | 7 | $357,479 | $-345,704 |
| Edwards Larry Todd | SVP Chief Commercial Officer | 1 | $7,767 | 3 | $169,742 | $-161,975 |
| Curran Terrie | director | 0 | $0 | 1 | $94,238 | $-94,238 |
| Topper David Joseph | Chief Financial Officer | 0 | $0 | 2 | $261,963 | $-261,963 |
| Welgus Howard G. | director | 0 | $0 | 11 | $1.31M | $-1.31M |
| Burnett Patrick | See Remarks | 0 | $0 | 14 | $1.86M | $-1.86M |
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Over the last 12 months, insiders at Arcutis Biotherapeutics, Inc. have bought $407,062 and sold $5.36M worth of Arcutis Biotherapeutics, Inc. stock.
On average, over the past 5 years, insiders at Arcutis Biotherapeutics, Inc. have bought $13.86M and sold $4.6M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Heron Patrick J (director) — $373,039. Watanabe Todd Franklin (See Remarks) — $14,482. Matsuda Masaru (See Remarks) — $11,775.
The last purchase of 2,646 shares for transaction amount of $34,610 was made by Heron Patrick J (director) on 2025‑06‑13.
| 2025-06-13 | Heron Patrick J | director | 2,646 0.0022% | $13.08 | $34,610 | +2.08% | ||
| 2025-06-05 | Heron Patrick J | director | 378 0.0003% | $13.41 | $5,069 | +3.08% | ||
| 2025-06-04 | Heron Patrick J | director | 1,890 0.0016% | $13.32 | $25,177 | +1.83% | ||
| 2025-05-28 | Sale | Matsuda Masaru | See Remarks | 1,800 0.0015% | $13.78 | $24,807 | -1.46% | |
| 2025-05-22 | Heron Patrick J | director | 2,520 0.0021% | $13.65 | $34,398 | -0.76% | ||
| 2025-05-21 | Heron Patrick J | director | 2,520 0.0021% | $13.66 | $34,423 | -4.04% | ||
| 2025-05-19 | Sale | Edwards Larry Todd | See Remarks | 7,451 0.006% | $14.07 | $104,850 | -5.26% | |
| 2025-05-15 | Heron Patrick J | director | 2,520 0.0021% | $13.62 | $34,317 | +1.41% | ||
| 2025-05-14 | Heron Patrick J | director | 6,300 0.0053% | $13.76 | $86,691 | -0.24% | ||
| 2025-05-13 | Heron Patrick J | director | 2,374 0.002% | $13.76 | $32,661 | -0.58% | ||
| 2025-05-09 | Heron Patrick J | director | 6,300 0.0053% | $13.60 | $85,691 | +1.49% | ||
| 2025-05-08 | Sale | Burnett Patrick | See Remarks | 3,871 0.0033% | $13.59 | $52,623 | -2.35% | |
| 2025-05-02 | Sale | Watanabe Todd Franklin | See Remarks | 11,448 0.0096% | $15.19 | $173,917 | -9.83% | |
| 2025-05-02 | Sale | Matsuda Masaru | See Remarks | 5,030 0.0042% | $15.20 | $76,453 | -9.83% | |
| 2025-05-02 | Sale | Burnett Patrick | See Remarks | 2,597 0.0022% | $15.19 | $39,442 | -9.83% | |
| 2025-05-01 | Sale | Welgus Howard G. | director | 10,000 0.0084% | $14.64 | $146,357 | -7.10% | |
| 2025-04-02 | Sale | Topper David Joseph | Chief Financial Officer | 9,600 0.0077% | $15.80 | $151,698 | -16.90% | |
| 2025-04-01 | Sale | Welgus Howard G. | director | 10,000 0.0085% | $15.12 | $151,236 | -7.79% | |
| 2025-03-25 | Sale | Watanabe Todd Franklin | See Remarks | 2,171 0.0019% | $17.56 | $38,131 | -18.88% | |
| 2025-03-24 | Sale | Watanabe Todd Franklin | See Remarks | 1,500 0.0013% | $17.52 | $26,282 | -19.52% |
| Watanabe Todd Franklin | See Remarks | 913795 0.7666% | $12.49M | 3 | 51 | +22.24% |
| Matsuda Masaru | See Remarks | 202599 0.17% | $2.77M | 2 | 15 | +37.68% |
| Edwards Larry Todd | See Remarks | 183104 0.1536% | $2.5M | 1 | 4 | |
| Topper David Joseph | Chief Financial Officer | 182774 0.1533% | $2.5M | 0 | 2 | |
| Burnett Patrick | See Remarks | 115468 0.0969% | $1.58M | 0 | 24 | |
| Welgus Howard G. | director | 111944 0.0939% | $1.53M | 0 | 40 | |
| Heron Patrick J | director | 27448 0.023% | $375,214.16 | 12 | 0 | <0.0001% |
| Curran Terrie | director | 10139 0.0085% | $138,600.13 | 0 | 1 | |
| Frazier Life Sciences VIII, L.P. | 10 percent owner | 8764232 7.3524% | $119.81M | 2 | 0 | +140.17% |
| ORBIMED ADVISORS LLC | 4267564 3.5801% | $58.34M | 2 | 0 | +10.62% | |
| SILVERSTEIN JONATHAN | 4267564 3.5801% | $58.34M | 2 | 0 | +10.62% | |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 3979292 3.3383% | $54.4M | 1 | 0 | +5.03% |
| CHAUDHURI BHASKAR | director | 841391 0.7059% | $11.5M | 0 | 9 | |
| OrbiMed Capital GP VII LLC | 415142 0.3483% | $5.67M | 0 | 2 | ||
| OSBORNE DAVID W | Chief Technical Officer | 268854 0.2255% | $3.68M | 0 | 10 | |
| Moore Matthew Richard | SVP and Chief Business Officer | 145505 0.1221% | $1.99M | 0 | 3 | |
| Lock Kenneth A. | Chief Commercial Officer | 63429 0.0532% | $867,074.43 | 0 | 6 | |
| Turney Patricia A. | SVP, Operations | 62862 0.0527% | $859,323.54 | 0 | 6 | |
| Burrows Scott L | Chief Financial Officer | 59115 0.0496% | $808,102.05 | 0 | 6 | |
| Smither John W | Chief Financial Officer | 46321 0.0389% | $633,208.07 | 0 | 7 |
$193,151,375 | 134 | 8.18% | $1.76B | |
$42,463,802 | 57 | 17.85% | $2.04B | |
$530,111,731 | 35 | 8.69% | $1.35B | |
$148,770,544 | 34 | 80.63% | $1.33B | |
$309,951,506 | 30 | 32.56% | $1.46B | |
$1,295,059 | 29 | 102.78% | $1.38B | |
$150,253,463 | 26 | -52.83% | $1.69B | |
$96,400,802 | 19 | 32.48% | $1.47B | |
$92,580,864 | 14 | -1.28% | $1.52B | |
Arcutis Biotherapeutics, Inc. (ARQT) | $137,027,226 | 13 | 28.32% | $1.63B |
$45,445,266 | 9 | -24.96% | $1.91B | |
$32,575,266 | 8 | 37.03% | $1.73B | |
$107,098,946 | 7 | 1.61% | $1.34B | |
$25,073,947 | 7 | -5.99% | $1.87B | |
$21,792,890 | 6 | 75.72% | $1.56B | |
$142,493,653 | 3 | 4.30% | $2.04B | |
$7,600,000 | 1 | -4.05% | $2B | |
$10,000,009 | 1 | 100.92% | $1.73B | |
$5,000,000 | 1 | -22.84% | $1.59B |
| Increased Positions | 130 | +51.59% | 8M | +6.57% |
| Decreased Positions | 111 | -44.05% | 12M | -8.96% |
| New Positions | 64 | New | 5M | New |
| Sold Out Positions | 31 | Sold Out | 969,339 | Sold Out |
| Total Postitions | 271 | +7.54% | 126M | -2.39% |
| Jennison Associates Llc | $188,058.00 | 10.37% | 12.34M | +676,295 | +5.8% | 2024-12-31 |
| Suvretta Capital Management, Llc | $173,723.00 | 9.58% | 11.4M | +677,627 | +6.32% | 2024-12-31 |
| Rubric Capital Management Lp | $167,132.00 | 9.22% | 10.97M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $135,519.00 | 7.47% | 8.89M | -256,221 | -2.8% | 2025-03-31 |
| Frazier Life Sciences Management, L.P. | $133,888.00 | 7.38% | 8.79M | 0 | 0% | 2024-12-31 |
| Polar Capital Holdings Plc | $112,431.00 | 6.2% | 7.38M | +493,009 | +7.16% | 2024-12-31 |
| Vanguard Group Inc | $98,156.00 | 5.41% | 6.44M | -521,920 | -7.5% | 2024-12-31 |
| State Street Corp | $75,449.00 | 4.16% | 4.95M | -690,906 | -12.25% | 2024-12-31 |
| Morgan Stanley | $64,677.00 | 3.57% | 4.24M | +462,716 | +12.24% | 2024-12-31 |
| Gilder Gagnon Howe & Co Llc | $59,482.00 | 3.28% | 3.9M | +349,153 | +9.82% | 2024-12-31 |